Medical/Pharmaceuticals
Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control
Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass and preventing post-treatment weight rebound. NEW ORLEANS, June 5, 2026 /PRNewswire/ -- Ractigen Therapeutics, a ...
2026-06-06 08:30
2363
SynbioTech Launches SYNMUE™ Targeting Immunosenescence, to Showcase at Probiota Americas 2026 in Vancouver
Clinical Study Showed Up to 48% Natural Killer Cell Increase with probiotic strain LP281 VANCOUVER, BC, June 5, 2026 /PRNewswire/ -- Synbio Tech Inc. (SynbioTech), a global leader in biotechnology solutions, today announced the launch of SYNMUE™, a clinically validated probiotic featuringLactipl...
2026-06-06 03:15
3413
Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the combination of an NTRK gene containing a kinase domain and its fusion partner gene. To date, mor...
2026-06-05 22:00
4433
Aphranel® Marks First Anniversary with EU MDR Certification, Arc™ Launch, and Over 150,000 Syringes Delivered
SHANGHAI, June 5, 2026 /PRNewswire/ -- On May 20, 2026, Aphranel® celebrated its first anniversary at the Waldorf Astoria Shanghai on the Bund, marking a major milestone in the brand's international presence in regenerative aesthetics. Highlights from the Aphranel® First Anniversary Summit in...
2026-06-05 13:20
2428
Mabwell's 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease
SHANGHAI, June 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative antibody drug 9MW5211 has received approval from the National Medical Products Adminis...
2026-06-05 11:30
2123
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
SINGAPORE, June 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub (Hub). Once operational, the facil...
2026-06-05 10:45
2759
Stronger Together, Shaping the Future | WuXi XDC and BioDlink Successfully Concluded 2026 Open Day
* WuXi XDC and BioDlink jointly hosted the 2026 Open Day, marking their first flagship customer-facing event following the strategic integration. * The event brought together biotech customers, industry leaders and innovators to explore how an integrated ADC/XDC CRDMO platform can accelerate ...
2026-06-04 20:30
1803
PharmaBlock's First Peptide GMP Pilot-scale Plant at PharmaBlock Zhejiang Site Now Operational
Next-Generation Peptide CRDMO Solutions Enabled by a Green and Intelligent Platform for Empowering Global Innovative Drug Development NANJING, China, June 4, 2026 /PRNewswire/ -- PharmaBlock Sciences (Stock Code: 300725.SZ) today announced the commissioning of its first peptide pilot-scale GMP p...
2026-06-04 20:21
1736
World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA
SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2026-06-04 16:35
2571
Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
GUANGZHOU, China, June 4, 2026 /PRNewswire/ -- Lupeng Pharmaceutical today announced that the National Medical Products Administration (NMPA) has granted accelerated approval to rocbrutinib (development code: LP-168) for the treatment of adult patients with relapsed or refractory mantle cell lymp...
2026-06-04 16:19
2067
111, Inc. Announces First Quarter 2026 Unaudited Financial Results
* Continuing Transition toward a More Asset-Light and Operationally Efficient Business Model * Net Revenue of Promotional Products (1) Increased by 70.2% and Gross Profit Rose by 75.0% Year-over-Year * Total Marketplace (MP) Service Revenue Increased by 24.7% Year-over-Year * Fulfillment E...
2026-06-04 16:00
4304
Early Data Show Highly Selective FGFR2 Inhibitor 3HP-2827 Active in Advanced CCA; Chinese Academy of Sciences' Zhou Jian Comments on Potential for Patients With FGFR2 Alterations
CHICAGO, June 2, 2026 /PRNewswire/ -- At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, 3H Pharmaceuticals released new clinical data for its wholly owned candidate, 3HP-2827. The ongoing study focuses on patients with advanced cholangiocarcinoma (CCA) and other solid tumor...
2026-06-02 21:30
4542
SK bioscience Secures First UNICEF Procurement Contract Improving Vaccine Access
* First UNICEF procurement contract strengthens SK bioscience's presence in global public procurement markets * Dual-hemisphere supply programs enhance manufacturing efficiency and operational capabilities * Public procurement programs drive both commercial growth and improved vaccine acces...
2026-06-02 20:00
2349
High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
CorrectSequence Therapeutics Reports Positive 15-Month Follow-Up Data for CS-206
SHANGHAI, June 2, 2026 /PRNewswire/ -- CorrectSequence Therapeutics Co., Ltd.
(Correctseq
2026-06-02 12:50
2902
/C O R R E C T I O N -- Ranok Therapeutics/
In the news release, Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic Non-Small Cell Lung Cancer Presented At ASCO 2026, issued 01-Jun-2026 by Ranok Therapeutics over PR Newswire, we are advised by the co...
2026-06-02 06:16
4888
3billion Launches 3B-NEO, a Genomic Newborn Screening Service Covering 595 Clinically Actionable Genetic Conditions
* Screens 595 carefully selected genes associated with childhood-onset conditions where early intervention may improve outcomes * Designed for maternity hospitals, obstetrics practices, newborn care providers, pediatric clinics and families seeking earlier genetic insights from birth * Expa...
2026-06-01 20:20
2956
Haisco Announces Licensing and Research Collaboration Agreement with Lilly to Develop Innovative Medicines Across Multiple Therapeutic Areas
SILICON VALLEY, Calif. and BEIJING, June 1, 2026 /PRNewswire/ -- On May 29, 2026, Haisco Pharmaceutical Group Co., Ltd. ("Haisco") (Ticker Code: 002653) announced a licensing and research collaboration with Eli Lilly and Company ("Lilly") to develop innovative medicines across multiple therapeuti...
2026-06-01 17:50
2550
China's Original Innovative Drug Cipepofol Approved for Marketing by the U.S. FDA
BEIJING, June 1, 2026 /PRNewswire/ -- Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class 1 innovative intravenous anesthetic independently developed by Haisco Pharmaceutical Group, has officially received marketing approval from the U.S. Food and Drug Administration (FDA), becoming ...
2026-06-01 15:04
2819
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
SHANGHAI, June 1, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 29 to June 2 (local time). As one of the world's leading oncology conferences, the ASCO Annual Meeting serves as a key venue for presenting advances in cancer r...
2026-06-01 13:51
3201
Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
HANGZHOU and SHANGHAI, China, June 1, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, todayannounced updated clinical data from its Phase I/II study evaluating ...
2026-06-01 12:00
4555
Week's Top Stories
Most Reposted
DayOne Secures Over 1GW Renewable Energy in Malaysia in Landmark TNB Partnership
[Picked up by 299 media titles]
2026-06-04 23:55
DayOne Data Centers Announces Final Closing of its Series C Equity Financing at US$4.5 Billion
[Picked up by 292 media titles]
2026-06-05 15:00Amartha Initiates Coalition to Advance Financial Health for Grassroots Communities in Indonesia
[Picked up by 291 media titles]
2026-06-05 19:08
FPT and NVIDIA Collaborate to Release the Nemotron Personas Vietnam Datasets
[Picked up by 276 media titles]
2026-06-05 17:34
Pudu Robotics and Shenzhen CTID Co. Ltd Launch the World's First Full-Scenario Robot-Serviced Hotel Project
[Picked up by 275 media titles]
2026-06-01 18:00Most Read
WePlay Korea's 4th Anniversary Celebration Kicks Off, Joining Hands with "Hello Panda-哈啰潘达" to Create Fu Bao Themed Space Decorations
2026-06-01 12:00
7003
NYSE Content Update: FedEx Freight to List on the NYSE + Join S&P 500
2026-06-01 21:32
6197
Hello Group Inc. Announces Unaudited Financial Results for the First Quarter of 2026
2026-06-02 15:33
5723
Mizuho becomes First Japanese Bank to Adopt SAP Multi-Bank Connectivity Solution
2026-06-02 15:00
5423
